Corbus Pharmaceuticals Holdings, INC 8-K filings

Corbus Pharmaceuticals Holdings, Inc. announced its second quarter 2026 financial results, highlighting progress in its oncology and obesity drug development programs, with key data readouts and study initiations expected in September 2026.

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer, effective August 3, 2026.

Corbus Pharmaceuticals announced updated Phase 1/2 clinical data for its CRB-701 drug, showing robust activity in oropharyngeal and cervical cancers, with plans for registrational trials.

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Nishant Saxena as Chief Business Officer and scheduled a conference call to discuss clinical data for its CRB-701 study.

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Brent Pfeiffenberger to its Board of Directors and the approval of an amendment to its 2024 Equity Compensation Plan.

Corbus Pharmaceuticals announced its Q1 2026 financial results, highlighting progress in its oncology and obesity programs with key data readouts and regulatory milestones anticipated.

Corbus Pharmaceuticals Holdings, Inc. has entered into amended and restated employment agreements with its CEO and CFO.

Corbus Pharmaceuticals has reached the 'Last Patient First Visit' milestone in its Phase 1b CANYON-1 clinical trial for CRB-913, an oral treatment for obesity.

Corbus Pharmaceuticals has reached an agreement with the FDA on registrational study designs for its lead antibody drug conjugate, CRB-701, targeting head and neck and cervical cancers.

Corbus Pharmaceuticals provides a comprehensive update on its clinical pipeline, showcasing promising safety and efficacy data for CRB-701 in solid tumors and CRB-913 in obesity, alongside strategic development plans.

Corbus Pharmaceuticals presents positive clinical data for its CRB-701, CRB-913, and CRB-601 programs, highlighting safety and efficacy advancements.

Alan Holmer has announced his retirement from the Board of Directors of Corbus Pharmaceuticals Holdings, Inc., effective December 31, 2025.

Corbus Pharmaceuticals announced positive Phase 1a data for its obesity drug CRB-913, demonstrating a favorable safety profile and early evidence of weight loss, alongside updates on its oncology pipeline.

Corbus Pharmaceuticals announced positive clinical data for CRB-701, progress in its obesity program CRB-913, and an extended cash runway into 2028 following a $75 million public offering.

Corbus Pharmaceuticals Holdings, Inc. announced the pricing of a public offering totaling approximately $75 million to advance its clinical development pipeline.

Corbus Pharmaceuticals Holdings, Inc. provided preliminary financial estimates for Q3 2025, reporting approximately $104.0 million in cash, cash equivalents, and investments.

Corbus Pharmaceuticals announced positive Phase 1/2 clinical data for CRB-701 in HNSCC, cervical, and urothelial cancers, demonstrating robust responses and a favorable safety profile.

Corbus Pharmaceuticals announced that its Nectin-4 targeting ADC, CRB-701, received FDA Fast Track designation for recurrent or metastatic head and neck squamous cell carcinoma.

Corbus Pharmaceuticals reported increased net losses for Q2 2025 but confirmed all three clinical programs are on track for significant data readouts in the second half of the year.

Corbus Pharmaceuticals held its annual meeting on May 15, 2025, electing directors, ratifying the appointment of EisnerAmper LLP, and appointing Rachelle Jacques as the new Chair of the Board.

Corbus Pharmaceuticals announced its Q1 2025 financial results, highlighting progress in its clinical programs for CRB-701, CRB-913, and CRB-601, with key data readouts expected in the second half of the year.

Dr. Peter Salzmann will not seek re-election to the Corbus Pharmaceuticals Board of Directors at the 2025 annual meeting, leading to a reduction in board size.

Corbus Pharmaceuticals Holdings, Inc. appoints Ian Hodgson as Chief Operating Officer, effective March 15, 2025.

Corbus Pharmaceuticals reports encouraging Phase 1 results for CRB-701, anticipates CRB-913 obesity study, and boasts a cash runway through Q3 2027.

Corbus Pharmaceuticals reports encouraging safety and efficacy data from its Phase 1 trial of CRB-701 (SYS6002), a next-generation Nectin-4 targeting ADC, including notable responses in head and neck squamous cell carcinoma (HNSCC).

Corbus Pharmaceuticals has been granted Fast Track designation by the FDA for its drug candidate CRB-701, aimed at treating relapsed or refractory metastatic cervical cancer.

A Corbus Pharmaceuticals board member, Anne Altmeyer, Ph.D., has established a Rule 10b5-1 plan to sell up to 2,452 shares of the company's common stock.

Corbus Pharmaceuticals announced its third quarter 2024 financial results and provided updates on its clinical programs, including the completion of enrollment for the dose escalation phase of its CRB-701 trial and the expected commencement of a Phase 1 trial for CRB-913 in Q1 2025.

Corbus Pharmaceuticals has released new pre-clinical data for CRB-913, a novel obesity treatment, showing significant weight loss and improved fat metabolism in mice.

Corbus Pharmaceuticals director, John Jenkins M.D., has adopted a Rule 10b5-1 plan to sell up to 5,436 shares of the company's common stock.